Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer

Pharmacogenomics Journal

Volumn 15, Issue 1, 2015, Pages 69-76

  Volz, N B ^a   Stintzing, S ^a   Zhang, W ^a   Yang, D ^b   Ning, Y ^a   Wakatsuki, T ^a,c   El Khoueiry, R E ^a   Li, J E ^a   Kardosh, A ^a   Loupakis, F ^d   Cremolini, C ^d   Falcone, A ^d   Scherer, S J ^e   Lenz, H J ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BINDING PROTEIN; BIOLOGICAL MARKER; FLUOROURACIL; FOLINIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEOCHONDROITIN SULFATE; RALA BINDING 1 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY;

AGED; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL FUNCTION; CELL MATURATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERICYTE; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR LOCALIZATION; ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; GENETICS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PERICYTES; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84921869876     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.40     Document Type: Article

References (38)

1. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-1121.
2. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
4. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
5. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
7. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013; 231: 63-76.
8. Stintzing S, Lenz HJ. Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together! Expert Opin Pharmacother 2013; 14: 2203-2220.
9. Harada K, Hiraoka S, Kato J, Horii J, Fujita H, Sakaguchi K et al. Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features. Br J Cancer 2007; 97: 1425-1431.
10. CancerGenomeAtlasNetwork. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
11. Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol 2013; 24: 2554-2559.
12. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013; 31: 1219-1230.
13. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro-oncology 2005; 7: 452-464.
14. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008; 456: 809-813.
15. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163-1177.
16. Rusanescu G, Gotoh T, Tian X, Feig LA. Regulation of Ras signaling specificity by protein kinase C. Mol Cell Biol 2001; 21: 2650-2658.
17. Lee S, Wurtzel JG, Singhal SS, Awasthi S, Goldfinger LE. RALBP1/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neovascularization. Cancer Res 2012; 72: 5165-5173.
18. Berger M, Bergers G, Arnold B, Hammerling GJ, Ganss R. Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood 2005; 105: 1094-1101.
19. Liu P, Zhang C, Chen J, Zhang R, Ren J, Huang Y et al. Combinational therapy of interferon-alpha and chemotherapy normalizes tumor vasculature by regulating pericytes including the novel marker RGS5 in melanoma. J Immunother 2011; 34: 320-326.
20. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013; 31: 1219-1230.
21. Bocci G, Loupakis F. Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle. Pharmacogenomics 2011; 12: 1077-1080.
22. Gerger A, LaBonte M, Lenz HJ. Molecular predictors of response to antiangiogenesis therapies. Cancer J 2011; 17: 134-141.
23. Flicek P, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D et al. Ensembl 2012. Nucleic Acids Res 2012; 40: D84-D90.
24. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009; 37: W600-W605.
25. Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 2008; 36: D820-D824.
26. Paez D, Gerger A, Zhang W, Yang D, Labonte MJ, Benhanim L et al. Association of common gene variants in the WNT/beta-catenin pathway with colon cancer recurrence. Pharmacogenom J 2013; 14: 142-150.
27. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 2008; 14: 7884-7895.
28. Conneely KN, Boehnke M. So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am Jl Hum Genet 2007; 81: 1158-1168.
29. Therneau TM, Atkinson EJ. An Introduction to Recursive Partitioning Using the RPART RoutinesMayo Foundation. Available at: http://cran.r-project.org/web/ packages/rpart/vignettes/longintro.pdf 2014; accessed on 1 March 2014.
30. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
31. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012; 22: 1790-1797.
32. Veyrieras JB, Kudaravalli S, Kim SY, Dermitzakis ET, Gilad Y, Stephens M et al. High-resolution mapping of expression-QTLs yields insight into human gene regulation. PLoS Genet 2008; 4: e1000214.
33. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, Attar-Cohen H et al. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 2009; 325: 1246-1250.
34. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008; 453: 410-414.
35. Barrett LW, Fletcher S, Wilton SD. Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell Mol Life Sci 2012; 69: 3613-3634.
36. Sambi BS, Hains MD, Waters CM, Connell MC, Willard FS, Kimple AJ et al. The effect of RGS12 on PDGFbeta receptor signalling to p42/p44 mitogen activated protein kinase in mammalian cells. Cell Signal 2006; 18: 971-981.
37. Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T et al. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with First-Line FOLFIRI plus bevacizumab. PLoS One 2013; 8: e66774.
38. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.